More than 90% of pancreatic ductal adenocarcinoma (PDAC) cases harbor activating mutations in the KRAS (Kristen’s rat sarcoma viral oncogene homolog (KRAS) gene1. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.